{"ticker": {"uuid": "ff588356-d255-49b7-b368-9d174cfc68c9", "symbol": "ABBV", "name": "AbbVie Inc.", "exchange": "MEX", "country": "MX", "sector": "Healthcare", "industry": "Drug Manufacturers - General"}, "articles": [{"title": "AbbVie (ABBV) Wins Canada Reimbursement Backing For Adult Migraine Treatment", "summary": "Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. AbbVie (NYSE: ABBV) received a recommendation from Canada's Drug Agency to reimburse UBRELVY for the acute treatment of migraine in adults. The decision follows Phase 3 trial results and a review process that included direct input from patients and clinicians. The recommendation expands access to UBRELVY in Canada and broadens AbbVie's neuroscience portfolio in migraine care. For more ideas in this area, take a look at 43 healthcare AI stocks.NYSE:ABBV E", "url": "https://finance.yahoo.com/healthcare/articles/abbvie-abbv-wins-canada-reimbursement-221514425.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-11T22:15:14+00:00", "published_display": "11 Aug 2026 22:15", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.396, "duplicate_count": 1, "topics": ["Biotech", "Canada Reimbursement", "Migraine Care", "Neuroscience", "Quarterly Results"]}, {"title": "AbbVie (ABBV) Gains On Botox Filing, Is The 9% Discount Still There?", "summary": "Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. AbbVie (ABBV) is back in focus after Allergan Aesthetics reported that the FDA accepted a supplemental Biologics License Application for Botox Cosmetic targeting masseter muscle prominence in adults, which would be a potential fifth U.S. aesthetic indication. See our latest analysis for AbbVie. Alongside Allergan Aesthetics' Botox update and several recent approvals and guidance changes, AbbVie's share price has moved to $247.97, with a 90 day share price return of 19.3% and a 1 year tot", "url": "https://finance.yahoo.com/healthcare/articles/abbvie-abbv-gains-botox-filing-211132588.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-11T21:11:32+00:00", "published_display": "11 Aug 2026 21:11", "sentiment": "negative", "sentiment_pct": 44, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.393, "duplicate_count": 1, "topics": ["Biotech", "Earnings", "Fda Approval", "Healthcare", "Share Price", "Shareholder"]}, {"title": "How Much Did Immunology Drugs Contribute to AbbVie's Q2 Performance?", "summary": "AbbVie ABBV announced encouraging second-quarter 2026 results last month, which beat expectations for both earnings and sales. A significant portion of this growth came from the continued strength of its two blockbuster immunology medications, Skyrizi and Rinvoq, which together accounted for more than 47% of total revenues. Skyrizi sales jumped 24% year over year on an operational basis to $5.5 billion, while Rinvoq sales rose 23.7% to more than $2.5 billion. Both drugs benefited from strong demand and market-share gains across their approved indications, especially in the popular inflammatory", "url": "https://finance.yahoo.com/healthcare/articles/much-did-immunology-drugs-contribute-165400709.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-11T16:54:00+00:00", "published_display": "11 Aug 2026 16:54", "sentiment": "positive", "sentiment_pct": 90, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.225, "duplicate_count": 1, "topics": ["Biotech", "Competition", "Earnings", "Fda Approval", "Immunology"]}, {"title": "Allergan Aesthetics Refreshes Allergan Partner Privileges\u00ae to Better Support Today's Modern Aesthetics Practices", "summary": "Updated program delivers simplified savings, greater benefits transparency, and expanded opportunities for practice growth Introduces new rewards opportunities for customer segments, including first-time APP members, growing practices, and long-standing loyal customers IRVINE, Calif., Aug. 11, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company, today announced updates to Allergan Partner Privileges\u00ae (APP), its customer portfolio loyalty program, designed to better support the way today's aesthetics practices operate and grow. Shaped by customer feedback and market momentum, the progra", "url": "https://finance.yahoo.com/healthcare/articles/allergan-aesthetics-refreshes-allergan-partner-120000677.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-11T12:00:00+00:00", "published_display": "11 Aug 2026 12:00", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.175, "duplicate_count": 1, "topics": []}, {"title": "AbbVie\u2019s (ABBV) Botox Just Got A Step Closer To A Fifth Use", "summary": "AbbVie (NYSE:ABBV) just moved a step closer to expanding one of its most recognizable brands. On August 4, the FDA accepted for review a supplemental Biologics License Application for Botox Cosmetic to treat masseter muscle prominence, the jaw-muscle bulge that can give a face a wider, squarer look. If cleared, Botox Cosmetic would become the first and only neurotoxin approved for that use in the US and the fifth aesthetic indication for a drug that already anchors AbbVie's fastest-growing units.AbbVie's (ABBV) Botox Just Got A Step Closer To A Fifth Use Bull Case: A Pipeline That Keeps Findin", "url": "https://finance.yahoo.com/healthcare/articles/abbvie-abbv-botox-just-got-165940206.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T16:59:40+00:00", "published_display": "10 Aug 2026 16:59", "sentiment": "positive", "sentiment_pct": 69, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.262, "duplicate_count": 1, "topics": ["Balance Sheet", "Biotech", "Debt", "Earnings", "Fda Approval", "Pharma"]}, {"title": "The 5 Most Interesting Analyst Questions From AbbVie\u2019s Q2 Earnings Call", "summary": "The 5 Most Interesting Analyst Questions From AbbVie's Q2 Earnings Call AbbVie's second quarter results reflected robust product performance but were met with cautious investor sentiment. Management credited double-digit sales growth to strong execution in core immunology therapies, especially SKYRIZI and RINVOQ, and notable gains in the neuroscience portfolio. CEO Robert Michael emphasized that \"each [portfolio] delivered growth above 20%,\" with SKYRIZI achieving market leadership in multiple countries. However, the quarter also saw persistent biosimilar pressure on legacy products and a comp", "url": "https://finance.yahoo.com/markets/stocks/articles/5-most-interesting-analyst-questions-233322850.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-09T23:33:22+00:00", "published_display": "09 Aug 2026 23:33", "sentiment": "positive", "sentiment_pct": 88, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.231, "duplicate_count": 1, "topics": ["Biotech", "Earnings", "Free Cash Flow", "Guidance", "Pharma", "Revenue Growth"]}, {"title": "AbbVie (ABBV) Is Down 5.3% After Raising 2026 Revenue Outlook and Issuing New Debt - What's Changed", "summary": "In late July and early August 2026, AbbVie reported stronger second\u2011quarter results, raised full\u2011year revenue guidance to about US$67.6 billion, advanced RINVOQ and BOTOX regulatory milestones, and completed a multi\u2011billion\u2011dollar mix of new fixed\u2011 and floating\u2011rate bond issuances. Together, these moves highlight how AbbVie is simultaneously expanding its immunology, neuroscience and aesthetics franchises while tapping debt markets to support its pipeline and deals such as the planned Apogee Therapeutics acquisition. Next, we'll examine how AbbVie's raised revenue outlook, alongside its expand", "url": "https://finance.yahoo.com/markets/stocks/articles/abbvie-abbv-down-5-3-201443622.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-07T20:14:43+00:00", "published_display": "07 Aug 2026 20:14", "sentiment": "negative", "sentiment_pct": 31, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.136, "duplicate_count": 1, "topics": ["Balance Sheet", "Bonds", "Earnings", "Guidance", "Pharma", "Share Price"]}], "by_tier": {"direct": [{"title": "AbbVie (ABBV) Wins Canada Reimbursement Backing For Adult Migraine Treatment", "summary": "Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. AbbVie (NYSE: ABBV) received a recommendation from Canada's Drug Agency to reimburse UBRELVY for the acute treatment of migraine in adults. The decision follows Phase 3 trial results and a review process that included direct input from patients and clinicians. The recommendation expands access to UBRELVY in Canada and broadens AbbVie's neuroscience portfolio in migraine care. For more ideas in this area, take a look at 43 healthcare AI stocks.NYSE:ABBV E", "url": "https://finance.yahoo.com/healthcare/articles/abbvie-abbv-wins-canada-reimbursement-221514425.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-11T22:15:14+00:00", "published_display": "11 Aug 2026 22:15", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.396, "duplicate_count": 1, "topics": ["Biotech", "Canada Reimbursement", "Migraine Care", "Neuroscience", "Quarterly Results"]}, {"title": "AbbVie (ABBV) Gains On Botox Filing, Is The 9% Discount Still There?", "summary": "Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. AbbVie (ABBV) is back in focus after Allergan Aesthetics reported that the FDA accepted a supplemental Biologics License Application for Botox Cosmetic targeting masseter muscle prominence in adults, which would be a potential fifth U.S. aesthetic indication. See our latest analysis for AbbVie. Alongside Allergan Aesthetics' Botox update and several recent approvals and guidance changes, AbbVie's share price has moved to $247.97, with a 90 day share price return of 19.3% and a 1 year tot", "url": "https://finance.yahoo.com/healthcare/articles/abbvie-abbv-gains-botox-filing-211132588.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-11T21:11:32+00:00", "published_display": "11 Aug 2026 21:11", "sentiment": "negative", "sentiment_pct": 44, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.393, "duplicate_count": 1, "topics": ["Biotech", "Earnings", "Fda Approval", "Healthcare", "Share Price", "Shareholder"]}, {"title": "How Much Did Immunology Drugs Contribute to AbbVie's Q2 Performance?", "summary": "AbbVie ABBV announced encouraging second-quarter 2026 results last month, which beat expectations for both earnings and sales. A significant portion of this growth came from the continued strength of its two blockbuster immunology medications, Skyrizi and Rinvoq, which together accounted for more than 47% of total revenues. Skyrizi sales jumped 24% year over year on an operational basis to $5.5 billion, while Rinvoq sales rose 23.7% to more than $2.5 billion. Both drugs benefited from strong demand and market-share gains across their approved indications, especially in the popular inflammatory", "url": "https://finance.yahoo.com/healthcare/articles/much-did-immunology-drugs-contribute-165400709.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-11T16:54:00+00:00", "published_display": "11 Aug 2026 16:54", "sentiment": "positive", "sentiment_pct": 90, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.225, "duplicate_count": 1, "topics": ["Biotech", "Competition", "Earnings", "Fda Approval", "Immunology"]}, {"title": "Allergan Aesthetics Refreshes Allergan Partner Privileges\u00ae to Better Support Today's Modern Aesthetics Practices", "summary": "Updated program delivers simplified savings, greater benefits transparency, and expanded opportunities for practice growth Introduces new rewards opportunities for customer segments, including first-time APP members, growing practices, and long-standing loyal customers IRVINE, Calif., Aug. 11, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company, today announced updates to Allergan Partner Privileges\u00ae (APP), its customer portfolio loyalty program, designed to better support the way today's aesthetics practices operate and grow. Shaped by customer feedback and market momentum, the progra", "url": "https://finance.yahoo.com/healthcare/articles/allergan-aesthetics-refreshes-allergan-partner-120000677.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-11T12:00:00+00:00", "published_display": "11 Aug 2026 12:00", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.175, "duplicate_count": 1, "topics": []}, {"title": "AbbVie\u2019s (ABBV) Botox Just Got A Step Closer To A Fifth Use", "summary": "AbbVie (NYSE:ABBV) just moved a step closer to expanding one of its most recognizable brands. On August 4, the FDA accepted for review a supplemental Biologics License Application for Botox Cosmetic to treat masseter muscle prominence, the jaw-muscle bulge that can give a face a wider, squarer look. If cleared, Botox Cosmetic would become the first and only neurotoxin approved for that use in the US and the fifth aesthetic indication for a drug that already anchors AbbVie's fastest-growing units.AbbVie's (ABBV) Botox Just Got A Step Closer To A Fifth Use Bull Case: A Pipeline That Keeps Findin", "url": "https://finance.yahoo.com/healthcare/articles/abbvie-abbv-botox-just-got-165940206.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T16:59:40+00:00", "published_display": "10 Aug 2026 16:59", "sentiment": "positive", "sentiment_pct": 69, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.262, "duplicate_count": 1, "topics": ["Balance Sheet", "Biotech", "Debt", "Earnings", "Fda Approval", "Pharma"]}, {"title": "The 5 Most Interesting Analyst Questions From AbbVie\u2019s Q2 Earnings Call", "summary": "The 5 Most Interesting Analyst Questions From AbbVie's Q2 Earnings Call AbbVie's second quarter results reflected robust product performance but were met with cautious investor sentiment. Management credited double-digit sales growth to strong execution in core immunology therapies, especially SKYRIZI and RINVOQ, and notable gains in the neuroscience portfolio. CEO Robert Michael emphasized that \"each [portfolio] delivered growth above 20%,\" with SKYRIZI achieving market leadership in multiple countries. However, the quarter also saw persistent biosimilar pressure on legacy products and a comp", "url": "https://finance.yahoo.com/markets/stocks/articles/5-most-interesting-analyst-questions-233322850.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-09T23:33:22+00:00", "published_display": "09 Aug 2026 23:33", "sentiment": "positive", "sentiment_pct": 88, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.231, "duplicate_count": 1, "topics": ["Biotech", "Earnings", "Free Cash Flow", "Guidance", "Pharma", "Revenue Growth"]}, {"title": "AbbVie (ABBV) Is Down 5.3% After Raising 2026 Revenue Outlook and Issuing New Debt - What's Changed", "summary": "In late July and early August 2026, AbbVie reported stronger second\u2011quarter results, raised full\u2011year revenue guidance to about US$67.6 billion, advanced RINVOQ and BOTOX regulatory milestones, and completed a multi\u2011billion\u2011dollar mix of new fixed\u2011 and floating\u2011rate bond issuances. Together, these moves highlight how AbbVie is simultaneously expanding its immunology, neuroscience and aesthetics franchises while tapping debt markets to support its pipeline and deals such as the planned Apogee Therapeutics acquisition. Next, we'll examine how AbbVie's raised revenue outlook, alongside its expand", "url": "https://finance.yahoo.com/markets/stocks/articles/abbvie-abbv-down-5-3-201443622.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-07T20:14:43+00:00", "published_display": "07 Aug 2026 20:14", "sentiment": "negative", "sentiment_pct": 31, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.136, "duplicate_count": 1, "topics": ["Balance Sheet", "Bonds", "Earnings", "Guidance", "Pharma", "Share Price"]}], "industry": [], "sector": []}, "total_fetched": 7, "total_unique": 7, "total_relevant": 7, "pipeline_health": {"providers_attempted": 1, "providers_with_results": 1, "raw_articles": 7, "unique_stories": 7, "duplicates_removed": 0, "relevant_stories": 7, "current_evidence": 7, "direct_evidence": 7, "eodhd_articles": 7, "eodhd": {"configured": true, "status": "healthy", "calls_used": 210, "call_budget": 500, "budget_used_pct": 42.0, "requests_made": 42, "last_success_at": "2026-08-13T06:15:30.644046+00:00", "newest_seen_at": "2026-08-13T06:03:00+00:00", "rate_limit": 1200, "rate_remaining": 1199, "last_error": "", "mapped_mentions": 3308, "unmapped_mentions": 1778}, "status": "healthy"}, "sentiment_summary": {"positive": 5, "negative": 2, "neutral": 0, "score": 60, "raw_score": 64, "total": 7, "evidence_count": 7, "effective_articles": 6.2, "direct_story_count": 7, "industry_story_count": 0, "sector_story_count": 0, "story_count": 7, "source_count": 1, "source_concentration": 1.0, "direct_share": 100, "dispersion": 18, "confidence": 70, "evidence_status": "measured", "score_version": "evidence-v4", "newest_article_at": "2026-08-11T22:15:14+00:00", "label": "Constructive news tone", "tone": "positive"}, "classifier": {"primary_event": "earnings", "primary_label": "Earnings", "confidence": 78, "events": [{"event": "earnings", "label": "Earnings", "weight": 3.0, "count": 5}, {"event": "general", "label": "Market update", "weight": 0.6, "count": 1}, {"event": "deals", "label": "Deals and strategy", "weight": 0.6, "count": 1}], "positive_events": 5, "negative_events": 2, "pipeline": {"providers_attempted": 1, "providers_with_results": 1, "raw_articles": 7, "unique_stories": 7, "duplicates_removed": 0, "relevant_stories": 7, "current_evidence": 7, "direct_evidence": 7, "eodhd_articles": 7, "eodhd": {"configured": true, "status": "healthy", "calls_used": 210, "call_budget": 500, "budget_used_pct": 42.0, "requests_made": 42, "last_success_at": "2026-08-13T06:15:30.644046+00:00", "newest_seen_at": "2026-08-13T06:03:00+00:00", "rate_limit": 1200, "rate_remaining": 1199, "last_error": "", "mapped_mentions": 3308, "unmapped_mentions": 1778}, "status": "healthy"}}, "market_context": {"has_market_context": true, "latest_close": 4185.0, "latest_week": "2026-08-07", "one_week_move": -4.6, "four_week_move": -4.2, "twelve_week_move": 14.8, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.063493, "market_dynamics_buy_signal": false, "relative_strength": 2.108581, "fair_value_gap": 19.2, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 47.4307, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-4.6% over one week, -4.2% over four weeks, trend active, and near fair-value range."}, "interpretation": {"label": "Positive news being faded", "tone": "negative", "classification": "positive_rejected", "summary": "Constructive headlines are not being rewarded by price, which raises a rejection flag.", "confidence": 66, "badges": ["Sentiment confirms active trend"], "opportunities": ["Constructive tone aligns with the Sharemaestro trend signal."], "risks": [], "event_label": "Earnings", "sentiment_word": "constructive"}, "charts": {"sources": [{"label": "finance.yahoo.com", "count": 7}], "tiers": [{"label": "Direct company coverage", "count": 7}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Earnings", "count": 5}, {"label": "Market update", "count": 1}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "60/100", "tone": "positive", "text": "Constructive news tone"}, {"label": "Evidence confidence", "value": "70/100", "tone": "positive", "text": "6.2 effective stories after overlap and weighting."}, {"label": "Market reaction", "value": "Positive news being faded", "tone": "negative", "text": "Constructive headlines are not being rewarded by price, which raises a rejection flag."}, {"label": "Primary event", "value": "Earnings", "tone": "positive", "text": "78/100 classification confidence."}, {"label": "Company focus", "value": "7", "tone": "positive", "text": "100% of weighted evidence is company-specific."}, {"label": "Evidence agreement", "value": "18/100", "tone": "positive", "text": "lower dispersion means the independent stories agree more closely."}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-4.6% over one week, -4.2% over four weeks, trend active, and near fair-value range."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "AbbVie (ABBV) Wins Canada Reimbursement Backing For Adult Migraine Treatment"}], "updated_at": "2026-08-13T06:19:20.626695+00:00", "detail_intelligence": {"headline": "Positive news being faded", "summary": "Constructive news tone is drawn from 7 fresh independent stories, including 7 company-specific items across 1 publishers.", "status": "measured", "metrics": [{"label": "Weighted tone", "value": 60, "display": "60", "tone": "positive", "note": "Constructive news tone"}, {"label": "Evidence confidence", "value": 70, "display": "70", "tone": "positive", "note": "solid confidence"}, {"label": "Company focus", "value": 100, "display": "100%", "tone": "positive", "note": "7 direct stories"}, {"label": "Evidence agreement", "value": 82, "display": "82", "tone": "positive", "note": "18/100 dispersion"}], "confidence_drivers": [{"label": "Sample depth", "value": 78, "note": "6.2 effective stories"}, {"label": "Source breadth", "value": 20, "note": "1 independent publishers"}, {"label": "Direct relevance", "value": 100, "note": "company-specific evidence share"}, {"label": "Freshness", "value": 72, "note": "recency-weighted evidence"}, {"label": "Agreement", "value": 82, "note": "cross-story consistency"}, {"label": "Source independence", "value": 0, "note": "lower publisher concentration"}], "freshness": 72, "source_independence": 0, "timeline": [{"date": "2026-07-24", "label": "24 Jul", "count": 0, "score": null, "tone": "neutral", "x": 42.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-25", "label": "25 Jul", "count": 0, "score": null, "tone": "neutral", "x": 87.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-26", "label": "26 Jul", "count": 0, "score": null, "tone": "neutral", "x": 133.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-27", "label": "27 Jul", "count": 0, "score": null, "tone": "neutral", "x": 179.4, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-28", "label": "28 Jul", "count": 0, "score": null, "tone": "neutral", "x": 225.2, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-29", "label": "29 Jul", "count": 0, "score": null, "tone": "neutral", "x": 271.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-30", "label": "30 Jul", "count": 0, "score": null, "tone": "neutral", "x": 316.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-31", "label": "31 Jul", "count": 0, "score": null, "tone": "neutral", "x": 362.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-01", "label": "01 Aug", "count": 0, "score": null, "tone": "neutral", "x": 408.4, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-02", "label": "02 Aug", "count": 0, "score": null, "tone": "neutral", "x": 454.2, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-03", "label": "03 Aug", "count": 0, "score": null, "tone": "neutral", "x": 500.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-04", "label": "04 Aug", "count": 0, "score": null, "tone": "neutral", "x": 545.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-05", "label": "05 Aug", "count": 0, "score": null, "tone": "neutral", "x": 591.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-06", "label": "06 Aug", "count": 0, "score": null, "tone": "neutral", "x": 637.4, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-07", "label": "07 Aug", "count": 1, "score": 31, "tone": "negative", "x": 683.2, "y": 169.6, "volume_height": 13.0, "volume_y": 253.0}, {"date": "2026-08-08", "label": "08 Aug", "count": 0, "score": null, "tone": "neutral", "x": 729.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-09", "label": "09 Aug", "count": 1, "score": 88, "tone": "positive", "x": 774.8, "y": 65.8, "volume_height": 13.0, "volume_y": 253.0}, {"date": "2026-08-10", "label": "10 Aug", "count": 1, "score": 69, "tone": "positive", "x": 820.6, "y": 100.4, "volume_height": 13.0, "volume_y": 253.0}, {"date": "2026-08-11", "label": "11 Aug", "count": 4, "score": 62, "tone": "positive", "x": 866.4, "y": 113.2, "volume_height": 52.0, "volume_y": 214.0}, {"date": "2026-08-12", "label": "12 Aug", "count": 0, "score": null, "tone": "neutral", "x": 912.2, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-13", "label": "13 Aug", "count": 0, "score": null, "tone": "neutral", "x": 958.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}], "timeline_points": "683.2,169.6 774.8,65.8 820.6,100.4 866.4,113.2", "timeline_has_signal": true, "timeline_start": "24 Jul", "timeline_mid": "03 Aug", "timeline_end": "13 Aug", "momentum": {"label": "Stable", "tone": "neutral", "recent_score": 64, "prior_score": 67, "delta": -3, "recent_count": 5, "prior_count": 2, "volume_delta": 3}, "freshness_buckets": [{"label": "Last 24 hours", "count": 0, "share": 0}, {"label": "1 to 3 days", "count": 5, "share": 71}, {"label": "4 to 7 days", "count": 2, "share": 29}, {"label": "8 to 30 days", "count": 0, "share": 0}], "source_profile": [{"label": "finance.yahoo.com", "count": 7, "share": 100, "score": 64, "tone": "positive"}], "event_profile": [{"label": "Earnings", "count": 5, "share": 71, "score": 67, "tone": "positive"}, {"label": "Deals and strategy", "count": 1, "share": 14, "score": 31, "tone": "negative"}, {"label": "Market update", "count": 1, "share": 14, "score": 62, "tone": "positive"}], "topics": [{"label": "Earnings", "count": 5, "share": 71}, {"label": "Biotech", "count": 5, "share": 71}, {"label": "Pharma", "count": 3, "share": 43}, {"label": "Fda Approval", "count": 3, "share": 43}, {"label": "Share Price", "count": 2, "share": 29}, {"label": "Guidance", "count": 2, "share": 29}, {"label": "Balance Sheet", "count": 2, "share": 29}, {"label": "Shareholder", "count": 1, "share": 14}, {"label": "Revenue Growth", "count": 1, "share": 14}, {"label": "Quarterly Results", "count": 1, "share": 14}], "supporting": [{"label": "Direct evidence", "text": "7 current stories are mapped specifically to ABBV."}, {"label": "Narrative agreement", "text": "Cross-story agreement is 82/100, indicating a comparatively coherent tape."}], "tempering": [{"label": "Source breadth", "text": "Only 1 publisher currently contribute to the measured read."}, {"label": "Price disagreement", "text": "Constructive headlines are not being rewarded by price, which raises a rejection flag."}], "supporting_heading": "What supports the read", "tempering_heading": "What tempers the read", "latest_observation": {"title": "AbbVie (ABBV) Wins Canada Reimbursement Backing For Adult Migraine Treatment", "summary": "Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. AbbVie (NYSE: ABBV) received a recommendation from Canada's Drug Agency to reimburse UBRELVY for the acute treatment of migraine in adults. The decision follows Phase 3 trial results and a review process that included direct input from patients and clinicians. The recommendation expands access to UBRELVY in Canada and broadens AbbVie's neuroscience portfolio in migraine care. For more ideas in this area, take a look at 43 healthcare AI stocks.NYSE:ABBV E", "url": "https://finance.yahoo.com/healthcare/articles/abbvie-abbv-wins-canada-reimbursement-221514425.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-11T22:15:14+00:00", "published_display": "11 Aug 2026 22:15", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.403, "duplicate_count": 1, "topics": ["Biotech", "Canada Reimbursement", "Migraine Care", "Neuroscience", "Quarterly Results"]}, "article_count": 7, "updated_at": "2026-08-13T03:49:10.402074+00:00"}, "price_sentiment_path": {"available": true, "price_points": [{"x": 42.0, "y": 130.2, "label": "13 Feb 2026", "close": 3983.65, "index": 100.0}, {"x": 77.6, "y": 137.2, "label": "20 Feb 2026", "close": 3933.07, "index": 98.7}, {"x": 113.1, "y": 148.3, "label": "27 Feb 2026", "close": 3853.11, "index": 96.7}, {"x": 148.7, "y": 109.9, "label": "06 Mar 2026", "close": 4129.78, "index": 103.7}, {"x": 184.2, "y": 133.2, "label": "13 Mar 2026", "close": 3962.16, "index": 99.5}, {"x": 219.8, "y": 169.8, "label": "20 Mar 2026", "close": 3698.2, "index": 92.8}, {"x": 255.4, "y": 161.3, "label": "27 Mar 2026", "close": 3759.17, "index": 94.4}, {"x": 290.9, "y": 149.0, "label": "03 Apr 2026", "close": 3848.12, "index": 96.6}, {"x": 326.5, "y": 173.2, "label": "10 Apr 2026", "close": 3673.2, "index": 92.2}, {"x": 362.1, "y": 181.0, "label": "17 Apr 2026", "close": 3617.41, "index": 90.8}, {"x": 397.6, "y": 203.5, "label": "24 Apr 2026", "close": 3455.0, "index": 86.7}, {"x": 433.2, "y": 169.7, "label": "01 May 2026", "close": 3699.0, "index": 92.9}, {"x": 468.7, "y": 204.2, "label": "08 May 2026", "close": 3450.0, "index": 86.6}, {"x": 504.3, "y": 177.2, "label": "15 May 2026", "close": 3644.81, "index": 91.5}, {"x": 539.9, "y": 159.8, "label": "22 May 2026", "close": 3770.0, "index": 94.6}, {"x": 575.4, "y": 163.3, "label": "29 May 2026", "close": 3745.0, "index": 94.0}, {"x": 611.0, "y": 146.4, "label": "05 Jun 2026", "close": 3866.94, "index": 97.1}, {"x": 646.6, "y": 142.2, "label": "12 Jun 2026", "close": 3896.79, "index": 97.8}, {"x": 682.1, "y": 155.6, "label": "19 Jun 2026", "close": 3800.29, "index": 95.4}, {"x": 717.7, "y": 84.5, "label": "26 Jun 2026", "close": 4312.95, "index": 108.3}, {"x": 753.2, "y": 76.3, "label": "03 Jul 2026", "close": 4372.53, "index": 109.8}, {"x": 788.8, "y": 76.9, "label": "10 Jul 2026", "close": 4367.94, "index": 109.6}, {"x": 824.4, "y": 59.3, "label": "17 Jul 2026", "close": 4495.0, "index": 112.8}, {"x": 859.9, "y": 55.8, "label": "24 Jul 2026", "close": 4520.0, "index": 113.5}, {"x": 895.5, "y": 74.5, "label": "31 Jul 2026", "close": 4385.0, "index": 110.1}, {"x": 931.1, "y": 102.3, "label": "07 Aug 2026", "close": 4185.0, "index": 105.1}], "sentiment_points": [{"x": 720.3, "y": 120.8, "label": "26 Jun 2026", "score": 55}, {"x": 733.7, "y": 120.8, "label": "29 Jun 2026", "score": 55}, {"x": 735.0, "y": 120.8, "label": "29 Jun 2026", "score": 55}, {"x": 736.9, "y": 119.0, "label": "29 Jun 2026", "score": 56}, {"x": 739.5, "y": 122.6, "label": "30 Jun 2026", "score": 54}, {"x": 740.3, "y": 122.6, "label": "30 Jun 2026", "score": 54}, {"x": 745.1, "y": 122.6, "label": "01 Jul 2026", "score": 54}, {"x": 752.9, "y": 122.6, "label": "02 Jul 2026", "score": 54}, {"x": 755.7, "y": 126.3, "label": "03 Jul 2026", "score": 52}, {"x": 757.3, "y": 124.5, "label": "03 Jul 2026", "score": 53}, {"x": 758.3, "y": 124.5, "label": "03 Jul 2026", "score": 53}, {"x": 758.8, "y": 124.5, "label": "04 Jul 2026", "score": 53}, {"x": 769.3, "y": 126.3, "label": "06 Jul 2026", "score": 52}, {"x": 779.8, "y": 119.0, "label": "08 Jul 2026", "score": 56}, {"x": 780.7, "y": 119.0, "label": "08 Jul 2026", "score": 56}, {"x": 785.7, "y": 119.0, "label": "09 Jul 2026", "score": 56}, {"x": 791.0, "y": 119.0, "label": "10 Jul 2026", "score": 56}, {"x": 791.9, "y": 120.8, "label": "10 Jul 2026", "score": 55}, {"x": 792.0, "y": 120.8, "label": "10 Jul 2026", "score": 55}, {"x": 795.1, "y": 119.0, "label": "11 Jul 2026", "score": 56}, {"x": 800.0, "y": 120.8, "label": "12 Jul 2026", "score": 55}, {"x": 800.4, "y": 120.8, "label": "12 Jul 2026", "score": 55}, {"x": 804.8, "y": 119.0, "label": "13 Jul 2026", "score": 56}, {"x": 806.0, "y": 119.0, "label": "13 Jul 2026", "score": 56}, {"x": 810.2, "y": 122.6, "label": "14 Jul 2026", "score": 54}, {"x": 811.5, "y": 122.6, "label": "14 Jul 2026", "score": 54}, {"x": 822.1, "y": 126.3, "label": "16 Jul 2026", "score": 52}, {"x": 822.7, "y": 124.5, "label": "16 Jul 2026", "score": 53}, {"x": 826.3, "y": 122.6, "label": "17 Jul 2026", "score": 54}, {"x": 839.1, "y": 124.5, "label": "19 Jul 2026", "score": 53}, {"x": 839.3, "y": 124.5, "label": "19 Jul 2026", "score": 53}, {"x": 840.4, "y": 124.5, "label": "20 Jul 2026", "score": 53}, {"x": 842.4, "y": 124.5, "label": "20 Jul 2026", "score": 53}, {"x": 846.7, "y": 124.5, "label": "21 Jul 2026", "score": 53}, {"x": 855.0, "y": 115.3, "label": "23 Jul 2026", "score": 58}, {"x": 876.0, "y": 122.6, "label": "27 Jul 2026", "score": 54}, {"x": 884.1, "y": 119.0, "label": "28 Jul 2026", "score": 56}, {"x": 886.3, "y": 122.6, "label": "29 Jul 2026", "score": 54}, {"x": 887.3, "y": 126.3, "label": "29 Jul 2026", "score": 52}, {"x": 887.5, "y": 128.2, "label": "29 Jul 2026", "score": 51}, {"x": 888.6, "y": 124.5, "label": "29 Jul 2026", "score": 53}, {"x": 889.5, "y": 126.3, "label": "29 Jul 2026", "score": 52}, {"x": 892.6, "y": 124.5, "label": "30 Jul 2026", "score": 53}, {"x": 898.0, "y": 133.7, "label": "31 Jul 2026", "score": 48}, {"x": 906.8, "y": 126.3, "label": "02 Aug 2026", "score": 52}, {"x": 908.1, "y": 126.3, "label": "02 Aug 2026", "score": 52}, {"x": 909.5, "y": 126.3, "label": "02 Aug 2026", "score": 52}, {"x": 911.5, "y": 126.3, "label": "03 Aug 2026", "score": 52}, {"x": 922.8, "y": 124.5, "label": "05 Aug 2026", "score": 53}, {"x": 933.2, "y": 126.3, "label": "07 Aug 2026", "score": 52}, {"x": 948.4, "y": 115.3, "label": "10 Aug 2026", "score": 58}, {"x": 958.0, "y": 109.8, "label": "12 Aug 2026", "score": 61}], "price_path": "42.0,130.2 77.6,137.2 113.1,148.3 148.7,109.9 184.2,133.2 219.8,169.8 255.4,161.3 290.9,149.0 326.5,173.2 362.1,181.0 397.6,203.5 433.2,169.7 468.7,204.2 504.3,177.2 539.9,159.8 575.4,163.3 611.0,146.4 646.6,142.2 682.1,155.6 717.7,84.5 753.2,76.3 788.8,76.9 824.4,59.3 859.9,55.8 895.5,74.5 931.1,102.3", "sentiment_path": "720.3,120.8 733.7,120.8 735.0,120.8 736.9,119.0 739.5,122.6 740.3,122.6 745.1,122.6 752.9,122.6 755.7,126.3 757.3,124.5 758.3,124.5 758.8,124.5 769.3,126.3 779.8,119.0 780.7,119.0 785.7,119.0 791.0,119.0 791.9,120.8 792.0,120.8 795.1,119.0 800.0,120.8 800.4,120.8 804.8,119.0 806.0,119.0 810.2,122.6 811.5,122.6 822.1,126.3 822.7,124.5 826.3,122.6 839.1,124.5 839.3,124.5 840.4,124.5 842.4,124.5 846.7,124.5 855.0,115.3 876.0,122.6 884.1,119.0 886.3,122.6 887.3,126.3 887.5,128.2 888.6,124.5 889.5,126.3 892.6,124.5 898.0,133.7 906.8,126.3 908.1,126.3 909.5,126.3 911.5,126.3 922.8,124.5 933.2,126.3 948.4,115.3 958.0,109.8", "price_change": 5.1, "sentiment_change": 6, "latest_close": 4185.0, "start_label": "13 Feb", "mid_label": "15 May", "end_label": "07 Aug"}, "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}